Childhood obesity is associated with changes in the serum metabolite profile

Simone Wahl1, Zhonghao Yu, Michaela Kleber

  • 1Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

Obesity Facts
|October 31, 2012
PubMed

Insights

Childhood obesity alters serum metabolite profiles, revealing potential biomarkers for oxidative stress and energy metabolism. These findings may offer new insights into the biological mechanisms driving pediatric obesity.

Area of Science:

  • Biochemistry
  • Pediatrics
  • Metabolomics

Background:

  • Serum metabolite profiles reflect metabolic processes and disease-related pathophysiological changes.
  • Investigating serum metabolites in obese children can provide insights into the biological mechanisms of childhood obesity.

Purpose of the Study:

  • To investigate serum metabolite concentrations in obese children compared to normal-weight children.
  • To identify potential metabolic biomarkers associated with childhood obesity.

Main Methods:

  • Mass spectrometry-based metabolomics approach analyzing 163 metabolites in serum samples.
  • Comparison of metabolite concentrations and ratios between 80 obese and 40 normal-weight children (ages 6-15).

Main Results:

  • Obese children exhibited distinct serum metabolite profiles compared to normal-weight children.
  • 14 metabolites and 69 metabolite ratios were significantly altered in obese children, indicating oxidative stress, altered sphingomyelin metabolism, β-oxidation, and energy expenditure pathways.
  • Pubertal stage did not correlate with metabolite concentration differences.

Conclusions:

  • Childhood obesity significantly impacts the serum metabolome composition.
  • Identified altered metabolites may serve as potential biomarkers for obesity.
  • Further replication in larger studies is needed to validate these findings and generate new hypotheses on obesity mechanisms.
Abstract

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...